Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02589340 · ClinicalTrials.gov registry record · Phase 1
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
A Phase 1 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02589340 is a Phase 1 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 6 participants.
The verdict
NCT02589340, a Phase 1 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
Interventions
- DRUG Placebo
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02589340
The ClinicalTrials.gov registry entry for NCT02589340 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02589340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02589340 about?
NCT02589340 is a clinical study titled "Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia". The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
What is the current status of trial NCT02589340?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-01. Estimated completion is 2021-02-23.
What interventions are being tested in trial NCT02589340?
The interventions under investigation include: Placebo (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT02589340?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.